Organoids are increasingly being used in clinical research and decision-making.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Advances in SurgeryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.JAMA. 2007; 297: 267-277
- Does long-term survival in patients with pancreatic cancer really exist? Results from the CONKO-001 study.J Surg Oncol. 2013; 108: 398-402
- Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.N Engl J Med. 2013; 369: 1691-1703
- Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.Lancet. 2017; 389: 1011-1024
- FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer.N Engl J Med. 2018; 379: 2395-2406
- FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.N Engl J Med. 2011; 364: 1817-1825
- The role of venous and arterial resection in pancreatic cancer surgery.Ann Surg Oncol. 2018; 25: 51-58
- Extended distal pancreatectomy with thoracic wall resection after neoadjuvant FOLFIRINOX: is there a limit of resection for pancreatic cancer after downstaging?.Ann Hepatobiliary Pancreat Surg. 2020; 24: 90
- Surgical treatment of metastatic pancreatic ductal adenocarcinoma: a review of current literature.Pancreatology. 2019; 19: 672-680
- Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.N Engl J Med. 2019; 381: 317-327
- PD-1 blockade in tumors with mismatch-repair deficiency.N Engl J Med. 2015; 372: 2509-2520
- Molecular profiling of patients with pancreatic cancer: initial results from the know your tumor initiative.Clin Cancer Res. 2018; 24: 5018-5027
- Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the know your tumor registry trial.Lancet Oncol. 2020; 21: 508-518
- Pilot study using molecular profiling of patients’ tumors to find potential targets and select treatments for their refractory cancers.J Clin Oncol. 2010; 28: 4877-4883
- Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy.Nat Med. 2011; 17: 500-503
- Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma.Nat Genet. 2015; 47: 1168-1178
- Genomic analyses identify molecular subtypes of pancreatic cancer.Nature. 2016; 531: 47-52
- Pancreatic cancer.Lancet. 2020; 395: 2008-2020
- Cancer modeling meets human organoid technology.Science. 2019; 364: 952-955
- Xenograft and organoid model systems in cancer research.EMBO J. 2019; 38: 1-11
- Organoid modeling of the tumor immune microenvironment.Cell. 2018; 175: 1972-1988.e16
- Pancreatic cancer cell lines as patient-derived avatars: genetic characterisation and functional utility.Gut. 2018; 67: 508-520
- Pancreatic cancer organoids recapitulate disease and allow personalized drug screening.Proc Natl Acad Sci U S A. 2019; 116: 26580-26590
- Patient-derived organoid pharmacotyping is a clinically tractable strategy for precision medicine in pancreatic cancer.Ann Surg. 2020; 272: 427-435
- Intra-tumour diversification in colorectal cancer at the single-cell level.Nature. 2018; 556: 437-462
- Single-cell transcriptomics reveals heterogeneity and drug response of human colorectal cancer organoids.Proc Annu Int Conf IEEE Eng Med Biol Soc EMBS. 2018; 2018: 2378-2381
- Modeling human digestive diseases with CRISPR-Cas9–modified organoids.Gastroenterology. 2019; 156: 562-576
- Organoid cultures recapitulate esophageal adenocarcinoma heterogeneity providing a model for clonality studies and precision therapeutics.Nat Commun. 2018; 9: 1-13
- A colorectal tumor organoid library demonstrates progressive loss of niche factor requirements during tumorigenesis.Cell Stem Cell. 2016; 18: 827-838
- Organoid cultures of early-onset colorectal cancers reveal distinct and rare genetic profiles.Gut. 2020; 69: 2165-2179
- Basal-like and classical cells coexistence in pancreatic cancer revealed by single cell analysis.bioRxiv. 2020; https://doi.org/10.1101/2020.01.07.897454
- Basal-like and classical cells coexist in pancreatic cancer revealed by single-cell analysis on biopsy-derived pancreatic cancer organoids from the classical subtype.FASEB J. 2020; 34: 12214-12228
- Single-cell analysis of patient-derived PDAC organoids reveals cell state heterogeneity and a conserved developmental hierarchy.Christian Conrad bioRxiv. 2020;
- A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer.Mol Cancer Ther. 2011; 10: 1311-1316
- Successful creation of pancreatic cancer organoids by means of EUS-guided fine-needle biopsy sampling for personalized cancer treatment.Gastrointest Endosc. 2018; 87: 1474-1480
- Organoid models of gastrointestinal cancers in basic and translational research.Nat Rev Gastroenterol Hepatol. 2020; 17: 203-222
- SynergyFinder 2.0: visual analytics of multi-drug combination synergies.Nucleic Acids Res. 2020; 48: W488-W493
- Automated microfluidic platform for dynamic and combinatorial drug screening of tumor organoids.Nat Commun. 2020; 11: 1-12
- Organoid profiling identifies common responders to chemotherapy in pancreatic cancer.Cancer Discov. 2018; 8: 1112-1129
- Patient-derived organoid models help define personalized management of gastrointestinal cancer.Br J Surg. 2018; 105: e48-e60
Article info
Publication history
Published online: July 06, 2021
Identification
Copyright
© 2021 Elsevier Inc. All rights reserved.
